293 related articles for article (PubMed ID: 27400930)
41. The HIV Dementia Scale: predictive power in mild dementia and HAART.
Bottiggi KA; Chang JJ; Schmitt FA; Avison MJ; Mootoor Y; Nath A; Berger JR
J Neurol Sci; 2007 Sep; 260(1-2):11-5. PubMed ID: 17482212
[TBL] [Abstract][Full Text] [Related]
42. HIV-1 infection and cognitive impairment in the cART era: a review.
Schouten J; Cinque P; Gisslen M; Reiss P; Portegies P
AIDS; 2011 Mar; 25(5):561-75. PubMed ID: 21160410
[TBL] [Abstract][Full Text] [Related]
43. HIV-associated neurocognitive disorder and HIV-associated myelopathy in a patient with a preserved CD4, but high viral load-a rarely reported phenomenon: a case report and literature review.
Ayele BA; Amogne W; Gemechu L
BMC Infect Dis; 2020 Aug; 20(1):574. PubMed ID: 32758161
[TBL] [Abstract][Full Text] [Related]
44. HIV-associated executive dysfunction in the era of modern antiretroviral therapy: A systematic review and meta-analysis.
Walker KA; Brown GG
J Clin Exp Neuropsychol; 2018 May; 40(4):357-376. PubMed ID: 28689493
[TBL] [Abstract][Full Text] [Related]
45. The complement system, neuronal injury, and cognitive function in horizontally-acquired HIV-infected youth.
McGuire JL; Gill AJ; Douglas SD; Kolson DL;
J Neurovirol; 2016 Dec; 22(6):823-830. PubMed ID: 27273074
[TBL] [Abstract][Full Text] [Related]
46. Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia--case report.
Andersson LM; Hagberg L; Rosengren L; Fuchs D; Blennow K; Gisslén M
BMC Infect Dis; 2006 Sep; 6():141. PubMed ID: 16978408
[TBL] [Abstract][Full Text] [Related]
47. Cerebrospinal fluid immune markers and HIV-associated neurocognitive impairments: A systematic review.
Williams ME; Stein DJ; Joska JA; Naudé PJW
J Neuroimmunol; 2021 Sep; 358():577649. PubMed ID: 34280844
[TBL] [Abstract][Full Text] [Related]
48. Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment.
Ulfhammer G; Edén A; Mellgren Å; Fuchs D; Zetterberg H; Hagberg L; Nilsson S; Yilmaz A; Gisslén M
AIDS; 2018 Sep; 32(15):2171-2178. PubMed ID: 30005007
[TBL] [Abstract][Full Text] [Related]
49. Neurocognitive Impairment in a Chronically Well-Suppressed HIV-Infected Population: The Dutch TREVI Cohort Study.
van den Dries LWJ; Wagener MN; Jiskoot LC; Visser M; Robertson KR; Adriani KS; van Gorp ECM
AIDS Patient Care STDS; 2017 Aug; 31(8):329-334. PubMed ID: 28753395
[TBL] [Abstract][Full Text] [Related]
50. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D
HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471
[TBL] [Abstract][Full Text] [Related]
51. Factors related to HIV-associated neurocognitive impairment differ with age.
Fogel GB; Lamers SL; Levine AJ; Valdes-Sueiras M; McGrath MS; Shapshak P; Singer EJ
J Neurovirol; 2015 Feb; 21(1):56-65. PubMed ID: 25404233
[TBL] [Abstract][Full Text] [Related]
52. Effort and neuropsychological performance in HIV-infected individuals on stable combination antiretroviral therapy.
Paul R; Rhee G; Baker LM; Vaida F; Cooley SA; Ances BM
J Neurovirol; 2017 Oct; 23(5):725-733. PubMed ID: 28895090
[TBL] [Abstract][Full Text] [Related]
53. Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection.
Hermansson L; Yilmaz A; Axelsson M; Blennow K; Fuchs D; Hagberg L; Lycke J; Zetterberg H; Gisslén M
J Neuroinflammation; 2019 Jan; 16(1):16. PubMed ID: 30678707
[TBL] [Abstract][Full Text] [Related]
54. Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex.
Gisslen M; Hagberg L; Brew BJ; Cinque P; Price RW; Rosengren L
J Infect Dis; 2007 Jun; 195(12):1774-8. PubMed ID: 17492593
[TBL] [Abstract][Full Text] [Related]
55. Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus.
Bogoch II; Davis BT; Venna N
J Infect; 2011 Sep; 63(3):236-9. PubMed ID: 21658774
[TBL] [Abstract][Full Text] [Related]
56. Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care.
McCombe JA; Vivithanaporn P; Gill MJ; Power C
HIV Med; 2013 Feb; 14(2):99-107. PubMed ID: 22994556
[TBL] [Abstract][Full Text] [Related]
57. No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau).
Krut JJ; Price RW; Zetterberg H; Fuchs D; Hagberg L; Yilmaz A; Cinque P; Nilsson S; Gisslén M
Virulence; 2017 Jul; 8(5):599-604. PubMed ID: 27435879
[TBL] [Abstract][Full Text] [Related]
58. Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment.
Sacktor N; Miyahara S; Evans S; Schifitto G; Cohen B; Haughey N; Drewes JL; Graham D; Zink MC; Anderson C; Nath A; Pardo CA; McCarthy S; Hosey L; Clifford D;
J Neurovirol; 2014 Dec; 20(6):620-6. PubMed ID: 25377444
[TBL] [Abstract][Full Text] [Related]
59. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain.
McArthur JC; McClernon DR; Cronin MF; Nance-Sproson TE; Saah AJ; St Clair M; Lanier ER
Ann Neurol; 1997 Nov; 42(5):689-98. PubMed ID: 9392567
[TBL] [Abstract][Full Text] [Related]
60. An initial screening for HIV-associated neurocognitive disorders of HIV-1 infected patients in China.
Zhang Y; Qiao L; Ding W; Wei F; Zhao Q; Wang X; Shi Y; Li N; Smith D; Chen D
J Neurovirol; 2012 Apr; 18(2):120-6. PubMed ID: 22411002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
